The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas

Genome Biology

Volumn 15, Issue 7, 2014, Pages

  Saraconi, Giulia ^a   Severi, Francesco ^a   Sala, Cesare ^a   Mattiuz, Giorgio ^a   Conticello, Silvestro G ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; APOLIPOPROTEIN B MRNA EDITING ENZYME; BENZAMIDE DERIVATIVE; CYTIDINE DEAMINASE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; APOBEC1 GENE; ARTICLE; BCR ABL GENE; BINDING AFFINITY; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EGFP GENE; ESOPHAGEAL ADENOCARCINOMA; EXOME; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PHENOTYPE; REPORTER GENE; RETROVIRIDAE; RNA EDITING; RPOB GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; ADENOCARCINOMA; ANIMAL; CELL LINE; CHICKEN; DRUG RESISTANCE; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; K562 CELL LINE; MUTATION; RAT;

ADENOCARCINOMA; ANIMALS; BENZAMIDES; CELL LINE; CHICKENS; CYTIDINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PYRIMIDINES; RATS;

EID: 84924341659     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-014-0417-z     Document Type: Article

References (66)

1. Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, Giannoni F, Teng BB, Davidson NO, Scott J: The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 1993, 268:20709-20712.
2. Teng B, Burant CF, Davidson NO: Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260:1816-1819.
3. Blanc V, Davidson NO: APOBEC-1-mediated RNA editing. Wiley Interdiscip Rev Syst Biol Med 2010, 2:594-602.
4. Conticello SG: The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008, 9:229.
5. Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM: Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol 2012, 23:258-268.
6. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
7. Di Noia JM, Neuberger MS: Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007, 76:1-22.
8. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
9. Refsland EW, Harris RS: The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 2013, 371:1-27.
10. Skuse GR, Cappione AJ, Sowden M, Metheny LJ, Smith HC: The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res 1996, 24:478-485.
11. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL: A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev 1997, 11:321-333.
12. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S, Papavasiliou FN: Transcriptome-wide sequencing reveals numerous APOBEC1 mRNAediting targets in transcript 3' UTRs. Nat Struct Mol Biol 2011, 18:230-236.
13. Anant S, Davidson NO: An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability. Mol Cell Biol 2000, 20:1982-1992.
14. Anant S, Murmu N, Houchen CW, Mukhopadhyay D, Riehl TE, Young SG, Morrison AR, Stenson WF, Davidson NO: Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 2004, 127:1139-1149.
15. Harris RS, Petersen-Mahrt SK, Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002, 10:1247-1253.
16. Petersen-Mahrt SK, Neuberger MS: In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J Biol Chem 2003, 278:19583-19586.
17. Severi F, Chicca A, Conticello SG: Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol Biol Evol 2011, 28:1125-1129.
18. Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK: Activationinduced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J Biol Chem 2004, 279:52353-52360.
19. Guo JU, Su Y, Zhong C, Ming GL, Song H: Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
20. Bishop KN, Holmes RK, Sheehy AM, Malim MH: APOBEC-mediated editing of viral RNA. Science 2004, 305:645.
21. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004, 14:1392-1396.
22. Ikeda T, Ohsugi T, Kimura T, Matsushita S, Maeda Y, Harada S, Koito A: The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res 2008, 36:6859-6871.
23. Petit V, Guétard D, Renard M, Keriel A, Sitbon M, Wain-Hobson S, Vartanian JP: Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol 2009, 385:65-78.
24. Ikeda T, Abd El Galil KH, Tokunaga K, Maeda K, Sata T, Sakaguchi N, Heidmann T, Koito A: Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Res 2011, 39:5538-5554.
25. Gee P, Ando Y, Kitayama H, Yamamoto SP, Kanemura Y, Ebina H, Kawaguchi Y, Koyanagi Y: APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. J Virol 2011, 85:9726-9736.
26. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL: Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A 1995, 92:8483-8487.
27. Blanc V, Henderson JO, Newberry RD, Xie Y, Cho SJ, Newberry EP, Kennedy S, Rubin DC, Wang HL, Luo J, Davidson NO: Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice. Cancer Res 2007, 67:8565-8573.
28. Robbiani DF, Nussenzweig MC: Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013, 8:79-103.
29. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, et al: Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993.
30. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370.
31. Burns MB, Temiz NA, Harris RS: Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013, 45:977-983.
32. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS: DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013, 2:e00534.
33. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013, 45:970-976.
34. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR: Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013, 3:246-259.
35. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, et al: Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
36. Arakawa H, Buerstedde JM: Activation-induced cytidine deaminasemediated hypermutation in the DT40 cell line. Philos Trans R Soc Lond B Biol Sci 2009, 364:639-644.
37. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 2005, 22:367-377.
38. Arakawa H, Saribasak H, Buerstedde JM: Activation-induced cytidine deaminase initiates immunoglobulin gene conversion and hypermutation by a common intermediate. PLoS Biol 2004, 2:E179.
39. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS: Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 2004, 337:585-596.
40. Suspène R, Aynaud MM, Guétard D, Henry M, Eckhoff G, Marchio A, Pineau P, Dejean A, Vartanian JP, Wain-Hobson S: Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci U S A 2011, 108:4858-4863.
41. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M: The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009, 16:232-245.
42. Orthwein A, Patenaude AM, Affar EB, Lamarre A, Young JC, Di Noia JM: Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90. J Exp Med 2010, 207:2751-2765.
43. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210.
44. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010, 5:e15074.
45. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN: Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005, 65:3146-3154.
46. Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, Lynch JP, Rustgi AK: Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS One 2008, 3:e3534.
47. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, et al: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013, 45:478-486.
48. Crooks GE, Hon G, Chandonia JM, Brenner SE: WebLogo: a sequence logo generator. Genome Res 2004, 14:1188-1190.
49. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ: The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004, 64:7629-7633.
50. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ: American Gastroenterological Association: American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52. quiz e13.
51. Ellsworth E, Jackson SA, Thakkar SJ, Smith DM, Finkelstein S: Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus. BMC Gastroenterol 2012, 12:181.
52. Streppel MM, Lata S, DelaBastide M, Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink FH, Offerhaus GJ, Antoniou E, Maitra A, McCombie WR: Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 2014, 33:347-357.
53. Küppers R, Dalla-Favera R: Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001, 20:5580-5594.
54. Landry S, Narvaiza I, Linfesty DC, Weitzman MD: APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 2011, 12:444-450.
55. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A: APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2012, 2:806.
56. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, Klimczak LJ, Kryukov GV, Malc E, Mieczkowski PA, Resnick MA, Gordenin DA: Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 2012, 46:424-435.
57. Lada AG, Dhar A, Boissy RJ, Hirano M, Rubel AA, Rogozin IB, Pavlov YI: AID/ APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct 2012, 7:47. discussion 47.
58. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, Garg M, Liu LZ, Yang H, Yin D, Shi ZZ, Jiang YY, Gu WY, Gong T, Zhang Y, Xu X, Kalid O, Shacham S, Ogawa S, Wang MR, Koeffler HP: Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014, 46:467-473.
59. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS: Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010, 38:4274-4284.
60. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T: Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003, 197:1173-1181.
61. Muto T, Okazaki IM, Yamada S, Tanaka Y, Kinoshita K, Muramatsu M, Nagaoka H, Honjo T: Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A 2006, 103:2752-2757.
62. Shen HM, Bozek G, Pinkert CA, McBride K, Wang L, Kenter A, Storb U: Expression of AID transgene is regulated in activated B cells but not in resting B cells and kidney. Mol Immunol 2008, 45:1883-1892.
63. Arakawa H, Hauschild J, Buerstedde JM: Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 2002, 295:1301-1306.
64. Conticello SG, Ganesh K, Xue K, Lu M, Rada C, Neuberger MS: Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. Mol Cell 2008, 31:474-484.
65. Arakawa H, Lodygin D, Buerstedde JM: Mutant loxP vectors for selectable marker recycle and conditional knock-outs. BMC Biotechnol 2001, 1:7.
66. Petersen-Mahrt SK, Harris RS, Neuberger MS: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002, 418:99-103.